Skip to main content
. 2020 Oct 30;11:580335. doi: 10.3389/fimmu.2020.580335

Figure 1.

Figure 1

Correlations of soluble PD-L1 (sPD-L1) levels with clinical factors. (A) Grade (I, II, III, and IV), (B) IDH-1 mutational status (mutation and wide type), (C) Ki-67 (≤27.5% and >27.5%), and (D) treatment method (Radiotherapy (RT), RT plus chemotherapy (CRT), CRT and beacizumab (CRT+T) before and after RT. ns, non-significant. *P < 0.05, **P < 0.01.